NO950136L - 4-amino-N-(4-metyl-4-piperidinyl)-2-metoksybenzamider - Google Patents
4-amino-N-(4-metyl-4-piperidinyl)-2-metoksybenzamiderInfo
- Publication number
- NO950136L NO950136L NO950136A NO950136A NO950136L NO 950136 L NO950136 L NO 950136L NO 950136 A NO950136 A NO 950136A NO 950136 A NO950136 A NO 950136A NO 950136 L NO950136 L NO 950136L
- Authority
- NO
- Norway
- Prior art keywords
- pct
- compounds
- halo
- hydrogen
- formula
- Prior art date
Links
- MDDISMWDWORIKY-UHFFFAOYSA-N 4-amino-2-methoxy-n-(4-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(N)=CC=C1C(=O)NC1(C)CCNCC1 MDDISMWDWORIKY-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 abstract 1
- 108091005479 5-HT2 receptors Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 229940054066 benzamide antipsychotics Drugs 0.000 abstract 1
- 150000003936 benzamides Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91430692A | 1992-07-17 | 1992-07-17 | |
| PCT/EP1993/001993 WO1994002462A1 (en) | 1992-07-17 | 1993-07-08 | 4-amino-n^_-(4-methyl-4-piperidinyl)-2-methoxybenzamides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO950136D0 NO950136D0 (no) | 1995-01-13 |
| NO950136L true NO950136L (no) | 1995-02-03 |
| NO303011B1 NO303011B1 (no) | 1998-05-18 |
Family
ID=25434170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO950136A NO303011B1 (no) | 1992-07-17 | 1995-01-13 | 4-amino-N-(4-metyl-4-piperidinyl)-2-metoksybenzamider |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US5498618A (no) |
| EP (1) | EP0650475B1 (no) |
| JP (1) | JP3257677B2 (no) |
| KR (1) | KR100243535B1 (no) |
| AT (1) | ATE184001T1 (no) |
| AU (1) | AU668208B2 (no) |
| CA (1) | CA2138150C (no) |
| DE (1) | DE69326245T2 (no) |
| DK (1) | DK0650475T3 (no) |
| ES (1) | ES2137996T3 (no) |
| FI (1) | FI109997B (no) |
| GR (1) | GR3031820T3 (no) |
| HK (1) | HK1010730A1 (no) |
| HU (1) | HUT71886A (no) |
| IL (1) | IL106356A (no) |
| NO (1) | NO303011B1 (no) |
| WO (1) | WO1994002462A1 (no) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9319534D0 (en) * | 1993-09-22 | 1993-11-10 | Boots Co Plc | Therapeutic agents |
| US5602124A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
| US5919934A (en) * | 1997-02-19 | 1999-07-06 | The George Washington University | Compounds, compositions, and methods for cancer imaging and therapy |
| AU5569800A (en) * | 1999-06-30 | 2001-01-31 | Santen Pharmaceutical Co. Ltd. | Brain sigma-1 receptor-binding ligand |
| KR20010017625A (ko) * | 1999-08-12 | 2001-03-05 | 윤재승 | 시사프라이드의 제조 방법 |
| GB0306604D0 (en) * | 2003-03-21 | 2003-04-30 | Curidium Ltd | Second medical use |
| ITRM20050390A1 (it) * | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| EP3233077A4 (en) | 2014-12-19 | 2018-08-08 | The Broad Institute Inc. | Dopamine d2 receptor ligands |
| EP3233799B1 (en) | 2014-12-19 | 2021-05-19 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
| CN110950843B (zh) * | 2019-11-28 | 2022-12-27 | 广东东阳光药业有限公司 | 取代的苯酰胺衍生物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1507462A (en) * | 1974-03-21 | 1978-04-12 | Gallardo Antonio Sa | N-heterocyclic substituted benzamides methods for their preparation and compositions containing them |
| US4962115A (en) * | 1981-10-01 | 1990-10-09 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| CA1183847A (en) * | 1981-10-01 | 1985-03-12 | Georges Van Daele | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| GB8718346D0 (en) * | 1987-08-03 | 1987-09-09 | Fordonal Sa | Substituted benzamides |
-
1993
- 1993-07-08 HU HU9500138A patent/HUT71886A/hu unknown
- 1993-07-08 ES ES93917661T patent/ES2137996T3/es not_active Expired - Lifetime
- 1993-07-08 DE DE69326245T patent/DE69326245T2/de not_active Expired - Fee Related
- 1993-07-08 AU AU47029/93A patent/AU668208B2/en not_active Ceased
- 1993-07-08 CA CA002138150A patent/CA2138150C/en not_active Expired - Fee Related
- 1993-07-08 KR KR1019940704644A patent/KR100243535B1/ko not_active IP Right Cessation
- 1993-07-08 AT AT93917661T patent/ATE184001T1/de not_active IP Right Cessation
- 1993-07-08 WO PCT/EP1993/001993 patent/WO1994002462A1/en active IP Right Grant
- 1993-07-08 DK DK93917661T patent/DK0650475T3/da active
- 1993-07-08 JP JP50417594A patent/JP3257677B2/ja not_active Expired - Fee Related
- 1993-07-08 EP EP93917661A patent/EP0650475B1/en not_active Expired - Lifetime
- 1993-07-15 IL IL106356A patent/IL106356A/xx not_active IP Right Cessation
-
1995
- 1995-01-06 US US08/367,111 patent/US5498618A/en not_active Expired - Fee Related
- 1995-01-13 NO NO950136A patent/NO303011B1/no unknown
- 1995-01-16 FI FI950180A patent/FI109997B/fi active
- 1995-10-27 US US08/549,243 patent/US5688814A/en not_active Expired - Fee Related
- 1995-10-27 US US08/549,242 patent/US5691358A/en not_active Expired - Fee Related
-
1998
- 1998-10-29 HK HK98111599A patent/HK1010730A1/xx not_active IP Right Cessation
-
1999
- 1999-11-10 GR GR990402913T patent/GR3031820T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU9500138D0 (en) | 1995-03-28 |
| US5498618A (en) | 1996-03-12 |
| ES2137996T3 (es) | 2000-01-01 |
| ATE184001T1 (de) | 1999-09-15 |
| DE69326245T2 (de) | 2000-05-18 |
| FI950180A (fi) | 1995-01-16 |
| DK0650475T3 (da) | 2000-03-20 |
| EP0650475B1 (en) | 1999-09-01 |
| DE69326245D1 (de) | 1999-10-07 |
| WO1994002462A1 (en) | 1994-02-03 |
| US5691358A (en) | 1997-11-25 |
| JP3257677B2 (ja) | 2002-02-18 |
| EP0650475A1 (en) | 1995-05-03 |
| FI109997B (fi) | 2002-11-15 |
| AU668208B2 (en) | 1996-04-26 |
| KR950702183A (ko) | 1995-06-19 |
| NO303011B1 (no) | 1998-05-18 |
| US5688814A (en) | 1997-11-18 |
| HK1010730A1 (en) | 1999-06-25 |
| FI950180A0 (fi) | 1995-01-16 |
| NO950136D0 (no) | 1995-01-13 |
| GR3031820T3 (en) | 2000-02-29 |
| IL106356A0 (en) | 1993-11-15 |
| CA2138150C (en) | 2005-04-19 |
| KR100243535B1 (ko) | 2000-03-02 |
| HUT71886A (en) | 1996-02-28 |
| IL106356A (en) | 1997-06-10 |
| JPH07509234A (ja) | 1995-10-12 |
| AU4702993A (en) | 1994-02-14 |
| CA2138150A1 (en) | 1994-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL315636A1 (en) | Cosmetic or pharmaceutic compositions containing magnipherine or its derivatives | |
| PT98064A (pt) | Processo para a preparacao de novos compostos anti-epilepticos, nomeadamente acidos aminoalcanofosfinicos n-substituidos | |
| ATE212547T1 (de) | Arzneizubereitungen enthaltend mikronisiertes nebivolol | |
| CZ208895A3 (en) | Novel imidazopyridine compounds, process for preparing such compounds and their salts, the use of said compounds and salts in the preparation of medicaments and a medicament containing thereof | |
| ES2123039T3 (es) | Nuevas 3-(hidroxi-bencilidenil)-indolin-2-onas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
| ATE165091T1 (de) | Gefässverengende substituierte aryloxyalkyldiamine | |
| MY117852A (en) | Alkylaminobenzothiazole and- benzoxazole derivatives | |
| NO303011B1 (no) | 4-amino-N-(4-metyl-4-piperidinyl)-2-metoksybenzamider | |
| ES8207124A1 (es) | Un procedimiento para la preparacion de derivados de aminas secundarias. | |
| FI972434A0 (fi) | Lamotrigiiniä sisältävä farmaseuttinen koostumus | |
| ES8404852A1 (es) | Procedimiento para preparar derivados de acidos isoquinolein-4-carboxilicos | |
| FI913713A0 (fi) | Nya bicykliska aminosubstituerade foereningar. | |
| BR9306870A (pt) | Derivados farmacologicamente ativos de (aminometila terciária) - benzenometanol |